Foundations Investment Advisors LLC Grows Position in Novo Nordisk A/S (NYSE:NVO)

Foundations Investment Advisors LLC lifted its stake in Novo Nordisk A/S (NYSE:NVO) by 13.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 154,404 shares of the company’s stock after buying an additional 17,839 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Novo Nordisk A/S were worth $13,282,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Novare Capital Management LLC raised its stake in Novo Nordisk A/S by 3.2% during the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after purchasing an additional 85 shares in the last quarter. Rosenberg Matthew Hamilton raised its stake in Novo Nordisk A/S by 2.5% during the third quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock valued at $454,000 after purchasing an additional 94 shares in the last quarter. Burns J W & Co. Inc. NY raised its stake in Novo Nordisk A/S by 1.9% during the third quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock valued at $647,000 after purchasing an additional 100 shares in the last quarter. Spinnaker Trust raised its stake in Novo Nordisk A/S by 1.1% during the third quarter. Spinnaker Trust now owns 9,615 shares of the company’s stock valued at $1,145,000 after purchasing an additional 100 shares in the last quarter. Finally, Marco Investment Management LLC raised its stake in Novo Nordisk A/S by 1.5% during the third quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock valued at $798,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.9 %

NYSE NVO opened at $87.19 on Monday. The company’s 50-day moving average price is $95.35 and its 200-day moving average price is $114.80. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market cap of $391.26 billion, a PE ratio of 27.95, a PEG ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on NVO shares. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.